$2.59T
Total marketcap
$167.51B
Total volume
BTC 50.07%     ETH 15.77%
Dominance

Sarepta Therapeutics SRPT Stock

123.97 USD {{ price }} 0.747662% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
11.64B USD
LOW - HIGH [24H]
122.33 - 125.41 USD
VOLUME [24H]
523.06K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-5.8 USD

Sarepta Therapeutics Price Chart

Sarepta Therapeutics SRPT Financial and Trading Overview

Sarepta Therapeutics stock price 123.97 USD
Previous Close 130.42 USD
Open 130.48 USD
Bid 0 USD x 900
Ask 0 USD x 1000
Day's Range 130.25 - 132.55 USD
52 Week Range 62.5 - 159.89 USD
Volume 695.51K USD
Avg. Volume 1.53M USD
Market Cap 12.26B USD
Beta (5Y Monthly) 1.001408
PE Ratio (TTM) N/A
EPS (TTM) -5.8 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 173.74 USD

SRPT Valuation Measures

Enterprise Value 11.57B USD
Trailing P/E N/A
Forward P/E 39.053413
PEG Ratio (5 yr expected) -0.14
Price/Sales (ttm) 12.56484
Price/Book (mrq) 17.199425
Enterprise Value/Revenue 11.86
Enterprise Value/EBITDA -21.469

Trading Information

Sarepta Therapeutics Stock Price History

Beta (5Y Monthly) 1.001408
52-Week Change 96.52%
S&P500 52-Week Change 20.43%
52 Week High 159.89 USD
52 Week Low 62.5 USD
50-Day Moving Average 130.6 USD
200-Day Moving Average 123.51 USD

SRPT Share Statistics

Avg. Volume (3 month) 1.53M USD
Avg. Daily Volume (10-Days) 738.09K USD
Shares Outstanding 93.15M
Float 89.11M
Short Ratio 2.21
% Held by Insiders 4.25%
% Held by Institutions 85.35%
Shares Short 4.42M
Short % of Float 4.95%
Short % of Shares Outstanding 4.73%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 1:6

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -114.30%
Operating Margin (ttm) -59.58%
Gross Margin -9.26%
EBITDA Margin -55.24%

Management Effectiveness

Return on Assets (ttm) -11.88%
Return on Equity (ttm) -142.098%

Income Statement

Revenue (ttm) 975.68M USD
Revenue Per Share (ttm) 11.11 USD
Quarterly Revenue Growth (yoy) 20.20%
Gross Profit (ttm) -78066000 USD
EBITDA -539008000 USD
Net Income Avi to Common (ttm) -1115218048 USD
Diluted EPS (ttm) -12.74
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 1.88B USD
Total Cash Per Share (mrq) 20.21 USD
Total Debt (mrq) 1.31B USD
Total Debt/Equity (mrq) 183.18 USD
Current Ratio (mrq) 4.635
Book Value Per Share (mrq) 7.652

Cash Flow Statement

Operating Cash Flow (ttm) -433567008 USD
Levered Free Cash Flow (ttm) -144391376 USD

Profile of Sarepta Therapeutics

Country United States
State MA
City Cambridge
Address 215 First Street
ZIP 02142
Phone 617 274 4000
Website https://www.sarepta.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 1162

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Q&A For Sarepta Therapeutics Stock

What is a current SRPT stock price?

Sarepta Therapeutics SRPT stock price today per share is 123.97 USD.

How to purchase Sarepta Therapeutics stock?

You can buy SRPT shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Sarepta Therapeutics?

The stock symbol or ticker of Sarepta Therapeutics is SRPT.

Which industry does the Sarepta Therapeutics company belong to?

The Sarepta Therapeutics industry is Biotechnology.

How many shares does Sarepta Therapeutics have in circulation?

The max supply of Sarepta Therapeutics shares is 93.86M.

What is Sarepta Therapeutics Price to Earnings Ratio (PE Ratio)?

Sarepta Therapeutics PE Ratio is now.

What was Sarepta Therapeutics earnings per share over the trailing 12 months (TTM)?

Sarepta Therapeutics EPS is -5.8 USD over the trailing 12 months.

Which sector does the Sarepta Therapeutics company belong to?

The Sarepta Therapeutics sector is Healthcare.

Sarepta Therapeutics SRPT included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
Nasdaq US Smart Pharmaceuticals NQSSPH 1454.2 USD
-0.47
1453.71 USD 1464.83 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2568.29 USD
+0.16
2566.7 USD 2581.47 USD
Nasdaq Next Generation 100 Inde NGX 1138.09 USD
-0.13
1137.73 USD 1146.36 USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD
NASDAQ Composite Total Return I XCMP 19565.06 USD
+0.82
19553.78 USD 19740.18 USD
NASDAQ Global Select Market Com NQGS 7837.41 USD
+0.85
7832.7 USD 7908.95 USD
NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD 2100.38 AUD 1390.15 USD
<0.01
2100.38 AUD 1390.15 USD 2100.38 AUD 1390.15 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD
NASDAQ Biotechnology Total Retu XNBI 4654.3 USD
-0.65
4652.69 USD 4696.7 USD